RFMP is a proprietary technology of GeneMatrix and can be utilized for genotyping viruses and microorganisms, and for human genome research.
RFMP was developed as a successor to the similar restriction fragment length polymorphism (RFLP) with the intent to allow for more SNPs.
[1] Like RFLP, the basic mechanism for RFMP is to run polymerase chain reaction (PCR) over a test sample.
Finally, MALDI-TOF is run on the fragments of interest to produce a m/z (mass-to-charge ratio) identification spectra of the individual nucleotides.
[4][5] Other limitations that hinder RFMP's spread in the medical world are attributed to its lack of information on SNP mutation rate[6] (e.g. masses have no correspondence to mutagenesis), as well as a general increase in user-handling difficulty compared to its peers.